Founded in 2020, Iambic Therapeutics integrates pioneering AI models, such as its Enchant multimodal transformer and NeuralPLexer structure predictor, with automated chemistry to run weekly design-make-test cycles. The platform is used to generate differentiated development candidates and has already delivered new drugs into human trials with what the company claims is unprecedented speed. Its lead asset, IAM1363, has shown anti-tumor activity and a favorable safety profile in HER2-wild-type and HER2-mutated cancers, and is now part of a clinical collaboration with Jazz Pharmaceuticals. Additional internal programs targeting KIF18A and CDK2/4 are expected to enter the clinic soon. Iambic is also engaged in a technology-enablement collaboration with Revolution Medicines that pairs proprietary data with NeuralPLexer capabilities. The company advances both wholly owned and partnered pipelines aimed at addressing urgent unmet needs. Backed by a recent oversubscribed financing of more than $100 million, Iambic is positioned to expand its pipeline, partnerships, and platform innovations.

Total raised

$250M

Funding rounds

3

Latest round

Equity

Latest activity

Nov 2025